by | Feb 6, 2023 | Uncategorized
Source: Cure Today articles The Food and Drug Administration granted an investigational new drug application and green lit the continued study of GC012F for the treatment of patients with relapsed/refractory myeloma. Read More
by | Feb 6, 2023 | Uncategorized
Chimeric antigen receptor T cells are one of the newest immunotherapy options for multiple myeloma treatment.Their novelty and effectiveness led to a surge in demand among a patient subgroup in dire need of new therapies for relapsed or refractory disease, leading to...
by | Feb 5, 2023 | Uncategorized
Source: Cure Today articles Post Content Read More
by | Feb 5, 2023 | Uncategorized
Source: Cure Today articles As a part of its Speaking Out Video series, CURE® spoke with Dr. Saad Usmani, on behalf of Throwing Bones for a Cure, about the future of multiple myeloma treatments. Read More
by | Feb 5, 2023 | Uncategorized
Source: Cure Today articles As a part of its Speaking Out Video series, CURE® spoke with Kenny Capps, from Throwing Bones for a Cure, about the impact multiple myeloma has on a patient’s mental health and what they can do to help themselves. Read...
by | Feb 5, 2023 | Uncategorized
Source: Cure Today articles As a part of its Speaking Out Video series, CURE® spoke with Kenny Capps, from Throwing Bones for a Cure, about the importance of staying active during a multiple myeloma diagnosis. Read More
